Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Dowlati, A.
Gray, R.
Johnson, D. H.
Schiller, J. H.
Brahmer, J.
Sandler, A. B.
机构：
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Univ Wisconsin, Madison, WI 53706 USA
[5] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：370S / 370S
页数：1
相关论文
共 50 条
  • [41] Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC)
    Saleh, M. N.
    Socinski, M. A.
    Trent, D.
    Dobbs, T.
    Zehngebot, L. M.
    Levine, M. A.
    Stella, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial
    Johnson, DH
    Paul, DM
    Hande, KR
    Shyr, Y
    Blanke, C
    Murphy, B
    Lewis, M
    DeVore, RF
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 2054 - 2060
  • [43] Tolerability and activity of weekly paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC)
    Fabi, A
    De Marco, S
    Barduagni, M
    Gamucci, T
    Cortesi, E
    De Marinis, F
    Ferraresi, V
    Saltarelli, R
    Gabriele, A
    Accettura, C
    Cognetti, F
    ANNALS OF ONCOLOGY, 2000, 11 : 4 - 4
  • [44] Concurrent chemoradiotherapy with paclitaxel and carboplatin for locoregionally advanced non-small cell lung cancer (NSCLC)
    Kaplanova, J.
    Tomiskova, M.
    Babickova, L.
    Kadlec, B.
    Slampa, P.
    Skrickova, J.
    LUNG CANCER, 2006, 52 : S34 - S34
  • [45] Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial
    Kosmidis, P
    Mylonakis, N
    Nicolaides, C
    Kalophonos, C
    Samantas, E
    Boukovinas, J
    Fountzilas, G
    Skarlos, D
    Economopoulos, T
    Tsavdaridis, D
    Papakostas, P
    Bacoyiannis, C
    Dimopoulos, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3578 - 3585
  • [46] Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC).
    McKeage, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 389S - 389S
  • [47] A phase II and pharmacogenomic study of Irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC).
    Pillot, GA
    Hennenfent, K
    Read, W
    Marsh, S
    McLeod, HL
    Gao, F
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 648S - 648S
  • [48] A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC)
    Fidias, P.
    Ciuleanu, T. A.
    Gladkov, O.
    Manikhas, G. M.
    Bondarenko, I. N.
    Pluzanska, A.
    Ramlau, R.
    Lynch, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [49] Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer
    Lilenbaum, RC
    Chen, CS
    Chidiac, T
    Schwarzenberger, PO
    Thant, M
    Versola, N
    Lane, SR
    ANNALS OF ONCOLOGY, 2005, 16 (01) : 97 - 101
  • [50] Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients
    Schmittel, A
    Siehl, JM
    Schulze, M
    Schulze, K
    Thiel, E
    Keilholz, U
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1333 - 1336
12345